Tirz3patid3, marketed as M0unjar0, is a once-weekly injectable medication approved in Portugal (late 2024) for the treatment of type 2 diabetes mellitus and obesity/overweight. It functions as a dual agonist of the GIP and GLP-1 receptors, enhancing satiety and reducing appetite, which results in clinically significant weight loss.
For research use only – Intended exclusively for qualified professionals conducting scientific research.